Biotech Consult appointed as Amhyspin CxO by Wallonia Biotech Coaching

Biotech Consult has been granted a CxO mandate by the Wallonia Biotech Coaching (WBC) incubator. This financial support will help the first spin-off project called AMHYSPIN - emerging from CECOTEPE / Haute Ecole de la Province de Liège - towards its full incorporation. The proper creation of the company is planned in January 2014.

Geoffrey Holsbeek, AMHYSPIN project leader and future CEO, declared: " we’re delighted by the granting of this mandate, which is partially subsidized by the Walloon Region, particularly because it brings an experienced manager - Didier Argentin from Biotech Consult - in the team ".

Serge Pampfer, CEO of WBC, is equally enthusiastic, saying " AMHYSPIN has developed a unique and proprietary technology enabling to boost the stability and productivity of valuable antibody-producing hybridoma cells and we are eager to help enhance the managerial capabilities of its team with the idea of speeding up the AMHYSPIN service platform towards the market ".

This CxO mandate is the second one awarded by WBC to Biotech Consult. The first mandate was dedicated to the spin-outting of CellTis, a subsidiary of the Liege-based company BIOPTIS that will be specifically focused on veterinary regenerative medicine.


About Amhyspin

AMHYSPIN is a spin-off emerging from «Centre de Coopération Technique et Pédagogique» (CECOTEPE), the research centre associated to the Haute École de la Province de Liège. AMHYSPIN has developed innovative technologies that increase the profitability of hybridoma cell lines producing monoclonal antibodies. After treatment, on the one hand, hybridoma cells secrete much longer thanks to stabilization and on the other hand, their production capabilities are multiplied. The whole « regeneration process » keeping the structure and potency of the mAb unchanged.

Contact : Geoffrey Holsbeek,,


About Wallonia Biotech Coaching

Created in 2006, WBC is the bio-incubator of the French-speaking Region of Belgium.

Its main mission is to assist operationally and financially biotech companies (spin-offs, spin-outs, start-ups) throughout their creation and growth stages. WBC brings together complementary competencies to support and accelerate the industrial and business challenges of the value chain model that emerging products and services companies need to overcome towards their respective markets. WBC helps companies developing bio-medical, environmental and agri-food applications as well as medical devices and life sciences-based systems and solutions.

Contact : Serge Pampfer,,

Écrire commentaire

Commentaires: 0